2026-01-12 - Analysis Report
# Comprehensive Analysis (Hims & Hers Health Inc., HIMS)

## Company Overview
Hims & Hers Health Inc. is a leading healthcare company providing innovative solutions for mental and physical well-being.

## Investment Diversification Analysis

* **Rate** (HIMS): 103.16%
* **Rate_vs** (VOO, S&P 500): 72.67%
* **Divergence**: $30.50
* This implies a cumulative return divergence of $30.50 between the review stock (HIMS) and the comparison stock (VOO). The relative divergence is at 27.90%, indicating that it's within the top 27.90% percentile in terms of divergence.
* The current position in the divergence range of HIMS (max: 325.50, min: -83.80, current: 30.50, relative divergence: 27.90%) suggests the review stock HIMS has recently experienced significant price movements compared to the comparison stock VOO (S&P 500).

### Performance Analysis
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2020-2022 | -19.0% | 67.1% | -17.0% | 0.7 | 1.5B |
| 2021-2023 | -65.0% | 67.1% | -66.0% | 1.6 | 2.0B |
| 2022-2024 | 119.0% | 42.0% | 99.0% | 1.7 | 5.5B |
| 2023-2025 | 114.0% | 57.5% | 52.0% | 2.1 | 7.4B |

* Performance metrics from Alpha, Beta Analysis:
 *   CAGR (2020-2022): -19.0%
 *   CAGR (2021-2023): -65.0%
 *   CAGR (2022-2024): 119.0%
 *   CAGR (2023-2025): 114.0%

## Recent Stock Price Fluctuations

*   **5-day SMA**: $34.24
*   **20-day SMA**: $34.82
*   **60-day SMA**: $39.79
* The stock price has fluctuated with the latest close at $31.69. The 5-day, 20-day and 60-day moving average (SMA) figures indicate short-term decline in stock price.

## RSI, PPO and Market Risk Indicator Analysis

*   **MRI**: 0.70 (Risk Level: Medium)
*   **RSI**: 35.53
*   **PPO**: 0.14
*   **Risk Level**: Medium (MRI 0.70)
*   **Recent (20 days) relative divergence change**: -3.50 (-): worsening
*   **7-day Rank change**: -5 (-): rank down
*   **7-day Dynamic Expected Return change**: 11.80 (+): improving
*   The current market risk indicator (MRI) is at 0.70 indicating a high potential for risk. The recent relative divergence change and 7-day Rank change are negative.

## Recent News and Significant Events

[2026-01-08] Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell? - Yahoo Finance (news.google.com)
[2026-01-09] Hims & Hers Health: Capitalizing On Healthcare Innovation (NYSE:HIMS) - Seeking Alpha (news.google.com)
[2026-01-09] Hims & Hers Health stock falls after Amazon Pharmacy adds Wegovy pill - Investing.com (news.google.com)
[2026-01-08] HIMS Stock Falls after BofA Slashes Price Target to a Street-Low of $29 - TipRanks (news.google.com)
[2026-01-08] Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth (NYSE:HIMS) - Seeking Alpha (news.google.com)
[2026-01-08] Hims & Hers Growth Story Has A Lot To Prove In 2026 (NYSE:HIMS) - Seeking Alpha (news.google.com)

## Analyst Opinions

Analyst Consensus:
- Key: Hold
- Mean (1=StrongBuy~5=Sell): 2.93 (~Hold)
- Opinions: 12
- Target Price (avg/high/low): 43.50 / 85.00 / 25.00

## Recent Earnings Analysis
| Date | EPS | Revenue |
|----- |----|---------|
| 2025-11-03 | 0.07 | $0.60 B |
| 2025-08-04 | 0.19 | $0.54 B |
| 2025-05-05 | 0.22 | $0.59 B |
| 2024-11-04 | 0.35 | $0.40 B |
| 2025-11-03 | 0.35 | $0.40 B |

## Financial Information (Revenue and Profitability)

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $0.60B | 73.80% |
| 2025-06-30 | $0.54B | 76.39% |
| 2025-03-31 | $0.59B | 73.50% |
| 2024-12-31 | $0.48B | 76.81% |
| 2024-09-30 | $0.40B | 79.16% |

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $0.58B | 2.72% |
| 2025-06-30 | $0.56B | 7.55% |
| 2025-03-31 | $0.55B | 9.01% |
| 2024-12-31 | $0.48B | 5.46% |
| 2024-09-30 | $0.44B | 17.18% |

The company has shown a mixed performance in recent years, with periods of high growth and significant price movements. However, the recent news and significant events suggest that the company's growth story has a lot to prove in 2026. The analyst consensus is to hold the stock, with a target price of $43.50. The financial information suggests that the company has a strong revenue growth and an increasing profit margin. However, the capital and profitability analysis indicates that the company's equity and return on equity (ROE) have decreased in some quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.